Karen BUSH, PhD
Professor of Practice and Interim Director of Biotechnology
Indiana University
Bloomington, Indiana
Disclosure: Allergan/Actavis : Grant/Research Support (Status: Terminated --- ); Bristol-Meyers Squibb : Other Financial or Material Support (Status: Ongoing), Retirement income (Status: Ongoing); Entasis : Advisor or Review Panel member (Status: Ongoing), Shareholder (Status: Ongoing); Fedora : Advisor or Review Panel member (Status: Ongoing), Consultant (Status: Ongoing), Shareholder (Status: Ongoing); Genentech : Consultant (Status: Ongoing); Gladius : Consultant (Status: Ongoing); Johnson & Johnson : Other Financial or Material Support (Status: Ongoing), Retirement income (Status: Ongoing), Shareholder (Status: Ongoing); Merck : Grant/Research Support (Status: Ongoing); Pfizer/AstraZeneca/Wyeth : Grant/Research Support (Status: Ongoing), Other Financial or Material Support (Status: Ongoing), Retirement income (Status: Ongoing); Shionogi : Advisor or Review Panel member (Status: Ongoing), Grant/Research Support (Status: Ongoing), Research Grant or Support (Status: Ongoing); Venatorx : Consultant (Status: Ongoing)
